PhaseRx Company Description

PhaseRx, Inc., a biopharmaceutical company, engages in developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy.

The company develops its products based on its proprietary Hybrid mRNA technology platform, which allows the synthesis of missing enzyme inside the cell.

Its therapeutic urea cycle disorder programs under development include PRX-OTC to treat ornithine transcarbamylase deficiency; PRX-ASL to treat argininosuccinate lyase deficiency; and PRX-ASS1 to treat argininosuccinate synthetase deficiency.

The company was incorporated in 2006 and is headquartered in Seattle, Washington.

PhaseRx, Inc.

Country	United States
Founded	2006
Industry	Biotechnology
Sector	Healthcare
Employees	10

Contact Details

Address: 410 West Harrison Street Seattle, Delaware 98119 United States
Phone	206 805 6300

Stock Details

Ticker Symbol	PZRXQ
Exchange	OTCMKTS
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	US71723F1030
SIC Code	2836

Key Executives

Name	Position
Dr. Robert W. Overell Ph.D.	Co-Founder and Director
Dr. Paul H. Johnson Ph.D.	Co-Founder and Director
Prof. Allan S. Hoffman	Co-Founder
Dr. Oliver W. Press M.D., Ph.D.	Co-Founder